Skip to main content
. 2022 Mar 17;6:16. doi: 10.1038/s41698-022-00260-0

Fig. 1. Lorlatinib intermediate resistant cells derived from JFCR-028-3 parental cells showed intermediate resistance to lorlatinib.

Fig. 1

a Schematic of the workflow to establish lorlatinib intermediate resistant cells from JFCR-028-3 parental cells, established after three cycles of drug treatment and a drug holiday. Scale bar = 100 μm. b Cell viability of JFCR-028-3 parental and lorlatinib intermediate resistant cells (n = 3). Each point represents the mean ± SD of three replicates. c Western blot analysis showing suppression of phospho-ALK and its downstream signaling in JFCR-028-3 parental and lorlatinib intermediate resistant cells treated with indicated concentrations of lorlatinib for 3 h. GAPDH was used as a loading control.